Eric Karas Sells Shares of ARS Pharmaceuticals

Eric Karas, the Chief Commercial Officer of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), sold 25,000 shares of the company on June 12, 2026. The shares were sold at an unspecified price, and the transaction was not part of a pre-planned trading program.

Insider Buying and Selling at ARS Pharmaceuticals, Inc.

Eric Karas, along with Alexander Fitzpatrick, the Chief Legal Officer, conducted multiple transactions on June 12, 2026. Karas sold 25,000 shares but also bought 25,000 shares at $1.50 each. Earlier in the year, on January 2, 2026, both Karas and Fitzpatrick acquired 240,000 shares each.

Other Institutional Activity in ARS Pharmaceuticals

Rubric Capital Management LP increased its holdings by 1.8 million shares, reaching a total of 8 million shares valued at approximately $64.2 million. Millennium Management LLC significantly boosted its position by 2.8 million shares, ending with 5.98 million shares worth about $48 million. Meanwhile, BlackRock, Inc. trimmed its stake by 73,063 shares, holding 5.01 million shares valued at $40.2 million.

ARS Pharmaceuticals Stock Snapshot

Shares of ARS Pharmaceuticals traded near $9.76. The company has a market cap of approximately $969.2 million and a forward P/E ratio that is not meaningful as the company isn't profitable. The stock's beta is 0.826, with a 52-week range of $6.66 to $18.90. Its 50-day moving average is $8.44, and the 200-day moving average is $9.43. ARS Pharmaceuticals maintains a strong liquidity position with a current ratio of 4.943 and a quick ratio of 4.645, though it has a high debt-to-equity ratio of 279.238.

Recent Earnings

ARS Pharmaceuticals reported revenue of about $98.99 million with a revenue growth rate of 1.845%. The company is not currently profitable, with a net margin of -200.004% and a return on equity of -136.403%. The next earnings report is expected on August 13, 2026.

Analysts Set New Price Targets

On May 28, 2026, Cantor Fitzgerald maintained a buy rating on ARS Pharmaceuticals with a price target of $30. Analysts generally have a strong buy consensus on the stock, with a target mean price of $28.80 based on five analyst opinions.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California. Founded in 2015, the company focuses on developing treatments for severe allergic reactions. Its flagship product, neffy, is a needle-free intranasal delivery system for epinephrine, intended for emergency treatment of Type I allergic reactions, including anaphylaxis. The company is led by CEO Mr. Richard E. Lowenthal and employs 154 people.

Bottom Line

Eric Karas's recent sale of shares at ARS Pharmaceuticals highlights ongoing insider activity at the company. Investors often track these transactions for potential insights into company sentiment. However, it's important to note that insider sales can occur for various reasons and do not necessarily indicate negative outlooks. The company's stock performance and analyst ratings suggest strong interest in its future prospects.